Instil Bio, Inc. (TIL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Instil Bio, Inc. is a biotechnology company focused on identifying and advancing therapeutic opportunities. In January 2026, the Company announced the discontinuation of its former lead product candidate, AXN-2510, developed by its subsidiary Axion Bio, Inc. The Company is actively seeking to in-license or acquire new therapeutic candidates. As of March 31, 2026, the Company had 6,781,976 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Loss | $(4.2) million | $(28.2) million |
| Net Loss Per Share | $(0.62) | $(4.32) |
| Total Operating Expenses | $7.0 million | $30.6 million |
| Research & Development | $0.7 million | $5.4 million |
| General & Administrative | $5.3 million | $9.1 million |
| Restructuring & Impairment | $1.0 million | $16.1 million |
| Cash & Cash Equivalents | $5.0 million | $10.6 million (end of period) |
| Marketable Securities | $69.5 million | $69.5 million |
| Total Liquidity (Cash + Securities) | $74.7 million | N/A |
| Debt (2024 Loan Principal) | $85.6 million | $85.6 million |
| Net Cash Used in Operating Activities | $(1.3) million | $(4.2) million |
Material Changes vs. Prior Period
- Significant Reduction in Net Loss: Net loss decreased by $24.0 million (85%) compared to Q1 2025, primarily driven by a $15.1 million reduction in restructuring and impairment charges and a $4.7 million decrease in R&D expenses.
- Discontinuation of AXN-2510: The termination of the AXN-2510 program in January 2026 led to a $1.6 million gain on contract termination and a sharp decline in R&D spend related to that candidate.
- Restructuring Charges: Q1 2026 charges of $1.0 million were related to employee terminations associated with the AXN-2510 discontinuation. This contrasts with Q1 2025, which included a $16.6 million impairment charge on the Tarzana facility.
- Operating Cash Flow: Cash used in operating activities improved significantly to $1.3 million from $4.2 million in the prior year, reflecting lower operating expenses and non-cash adjustments.
Outlook, Risks, and Management Commentary
- Going Concern Status: Management identified substantial doubt about the Company's ability to continue as a going concern due to the $85.6 million 2024 Loan maturing in January 2027, which exceeds current cash and marketable securities. However, management concluded that plans to exercise a contractual extension option to January 2028 alleviate this doubt.
- Tarzana Facility Strategy Change: In May 2026 (subsequent to the reporting period), the Board discontinued the plan to sell the Tarzana facility. The asset, currently classified as "held for sale" at $112.1 million, will be reclassified as "held and used" in Q2 2026, with the financial impact to be recognized then.
- Liquidity Plan: The Company intends to fund operations through existing cash, marketable securities, rental income from the Tarzana facility (approx. $7.5 million annually), and potential equity or debt financing. An "At-The-Market" (ATM) program remains available with approximately $93.1 million remaining capacity.
- Risks: Key risks include the inability to secure additional financing on favorable terms, the uncertainty of future product development, and the requirement to meet debt covenants to extend the 2024 Loan.
Investor Verification Checklist
- Debt Extension Feasibility: Verify the specific conditions required to exercise the one-year extension option on the $85.6 million 2024 Loan (due Jan 2027) and the Company's ability to meet debt yield and coverage ratios.
- Tarzana Facility Reclassification: Monitor Q2 2026 filings for the financial impact of reclassifying the Tarzana facility from "held for sale" to "held and used," including potential impairment adjustments.
- Pipeline Progress: Assess the timeline and capital requirements for in-licensing or acquiring new therapeutic candidates to replace the discontinued AXN-2510 program.
- Burn Rate vs. Liquidity: Confirm that the current cash burn rate (approx. $1.3 million operating cash outflow in Q1) is sustainable given the $74.7 million liquidity position and the upcoming debt maturity.